Execution of Securities Purchase Agreement with FIMI Opportunity Fund, an Existing Strategic Investor, to Support Kamada’s Growth Plans and Execution of Strategic Business Opportunities Rehovot, Israel – January 21, 2020 – Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today that it has entered into a securities purchase agreement with FIMI […]
Full-Year 2019 Revenue Expected to be Between $126.5 Million and $127.5 Million, in-line with Company’s Prior Revenue Guidance Company Expects Full-Year 2020 Total Revenue to be Between $132 Million and $137 Million Expected 2020 Revenue Growth Compared to 2019 Anticipated to be Driven by Increased Sales of KEDRAB® in the U.S., as well as the […]
Rehovot, Israel, December 16, 2019 — Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today that the first patient has been randomized in Europe into its pivotal Phase 3 InnovAATe clinical trial evaluating the safety and efficacy of the Company’s proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 […]
Commercial supply of the 12-year contract manufacturing agreement, following the completion of the required tech-transfer project, is expected to commence in early 2023 Based on current market sales volume, the new product is estimated to add approximately $8 million to $10 million in annual revenues to Kamada Gross margin level of the new product is […]
REHOVOT, Israel – December 2, 2019 — Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), today announced that it has entered into an agreement with Alvotech, a global biopharmaceutical company, to commercialize Alvotech’s portfolio of six biosimilar product candidates in Israel, upon receipt of regulatory approval from the Israeli Ministry of Health (IMOH). Kamada leverages its expertise […]
Total Revenues for Third Quarter and First Nine Months of 2019 were $33.1 Million and $95.1 Million, Respectively, Compared to $15.0 Million and $66.3 Million in the Respective Periods in 2018. As a Reminder, Kamada’s Third Quarter 2018 Performance was Impacted by the Then Labor Strike in the Company’s Manufacturing Facility. Gross Profit for Third […]
Rehovot, Israel, November 7, 2019 — Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the third quarter and nine months ended September 30, 2019, prior to the open of the U.S. financial markets on Wednesday, November 13, 2019. Kamada management will host an […]
The Successful Study was Basis for U.S. Food & Drug Administration Approval of KEDRAB® in 2017 Post-Marketing U.S. Pediatric Study Data Expected in 2H ‘2020 Abstract will be Presented at the Upcoming 2019 Rabies In The Americas (RITA) Conference Rehovot, Israel and Fort Lee, NJ, USA– October 29, 2019 – Kamada Ltd. (NASDAQ: KMDA; TASE: […]
REHOVOT, Israel – September 24, 2019 – Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived protein therapeutics company, announced today that Amir London, Chief Executive Officer, will provide a corporate overview at the 2019 Cantor Global Healthcare Conference, being held October 2-4, 2019, in New York City. The presentation will take place on Friday, October […]
Based on the Extended Term, Kamada Projects Revenues from Sales of GLASSIA to Takeda During 2019-2021 to be in the Range of $155 Million to $180 Million Based on Current GLASSIA U.S. Sales and Forecasted Growth, Kamada Projects to Receive Royalties from Takeda in the Range of $10 Million to $20 Million Per Year from […]